MYD88 and diffuse large B-cell lymphoma: As previously reported, TLR9, in combination with BCR as well as mutant isoforms of MYD88, could result in sustained activity of NF-κB in the activated B-cell-like subtype of diffuse large B-cell lymphoma [44].